Home › Forums › Main Forum › FixHepC Admin › Gilead to Cease HCV R & D

Viewing 3 posts - 16 through 18 (of 18 total)
1 2
  • Author
    Posts
  • 6 November 2016 at 4:31 pm #24196
    vitrus
    • Topics: 1
    • Replies: 35
    • Total: 36
    • Treatment Warrior
    • ★★★
    @vitrus

    Other companies will focus on the developing world and retreatment therapies.

    Gen 1b
    VL pre treatment 29000 ME/ml
    AST 32 ALT 94, F0
    Started treatment 13 January 2017
    Generic sofosbuvir/velpatasvir (Incepta)
    VL 9 days into treatment <300 (undetected)
    AST 13.8 ALT 22
    Side effects: mild dehydration, not a problem at all if I drink water at night, nothing to worry about
    Diet and gastric ph are very important with velpatasvir. One must think what and when to eat to keep gastric pH low. Side effects disappeared 2 weeks after, unless I ate anything < 4hrs before the pill. SVR60.

    6 November 2016 at 10:54 pm #24202
    Avatar photosplitdog
    • Guardian Angel
    • ★★★★★
    @splitdog

    ROHCVfighter– Yes, I probably would invest elsewhere, too.

    Who knows? Maybe Gilead’s greed will make them abandon HCV for more ‘lucrative’ drugs–maybe to treat cancer– and they can overprice them to the point where generics can come into the picture and again cure many. :)

    splitdog@roadrunner.com

    Genotype 3
    VL 4,100,000
    ALT 101 AST 71
    Treatment Naive
    Started Sof/Dac Jan 12, 2016
    VL= <15 4 weeks in. AST/ALT normal.
    VL=UNDETECTED 8 weeks in.
    SVR4= Virus back. 3,300,000

    Started generic Epclusa Sep. 23, 2017

    4 weeks in <15 *Detected.
    12 weeks in <15 *Not Detected.
    16 weeks in <15 *Not Detected.
    Finished 24 weeks treatment 3-17-18
    SVR5 <15 Not Detected.
    SVR 20 <15 Not Detected.
    SVR 44 <15 Not Detected.

    Thank you Jesus.
    Thank you Dr. James

    7 November 2016 at 7:11 am #24207
    dope-on-a-rope.jpgDr James
    • Guardian Angel
    • ★★★★★
    @fixhepc

    If you look at it logically from the point of return on investment.

    90% cure (Sof+Riba or Sof+Led) – leaves 10%

    90% cure (Sof+Vel) in that 10% leaves 1%

    90% cure (Sof+Vel+Vox) in that 1% leaves 0.1%

    0.1% of 180 million is “only” 180,000 total patients versus 179,820,000 who could have access to curative medication that already exists.

    With ABT-493 3 x better than GS-9857 (Vox) and ABT-530 10 x better than Velpatasvir for all intents and purposes 99.9%+ of people can be cured with existing medications.

    The issue we have is not further invention. It’s deployment on an industrial scale.

    YMMV

  • Author
    Posts
Viewing 3 posts - 16 through 18 (of 18 total)
1 2
  • You must be logged in to reply to this topic.